News

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

July 20, 2023
Jeanne Bolger and Andre Hoekema Sapreme Board of Directors
Read more
Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

MIMETAS and Astellas Expand Partnership to Include Automation and Application Support

June 20, 2023
MIMETAS and Astellas expand partnership.
Read more
MIMETAS and Astellas Expand Partnership to Include Automation and Application Support

MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology

March 28, 2023
Strategic Partnership Mimetas - Astellas
Read more
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology

Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

March 16, 2023
U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane th...
Read more
Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

CliCr® and CliCr® derivatives are available via Iris Biotech GmbH

January 26, 2023
Iris Biotech sells CliCr® and CliCr® reagents.
Read more
CliCr® and CliCr® derivatives are available via Iris Biotech GmbH

Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering

January 17, 2023
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox...
Read more
Lonza Collaborates with Cristal Therapeutics and  McSAF to Expand Bioconjugates Offering

MIMETAS Elected Most Innovative Company of the Netherlands

November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
MIMETAS Elected Most Innovative Company of the Netherlands

Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

Professor Melief to receive 2022 SITC Pedro J. Romero Award

September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award

MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors

Home > News

© 2023 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds